PubMed

Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG.

Br J Haematol. 2009 Nov 6. [Epub ahead of print]PMID: 19895616 [PubMed - as supplied by publisher]Related articles

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse.

Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M.

Leuk Res. 2009 Oct 28. [Epub ahead of print]PMID: 19878996 [PubMed - as supplied by publisher]Related articles

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.

Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H.

J Clin Oncol. 2009 Nov 10;27(32):5425-30. Epub 2009 Oct 5.PMID: 19805674 [PubMed - in process]Related articles

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.

Ravandi F, Issa JP, Garcia-Manero G, O'Brien S, Pierce S, Shan J, Borthakur G, Verstovsek S, Faderl S, Cortes J, Kantarjian H.

Cancer. 2009 Sep 30. [Epub ahead of print]PMID: 19795507 [PubMed - as supplied by publisher]Related articles

Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.

Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F.

Leukemia. 2009 Sep 10. [Epub ahead of print]PMID: 19741728 [PubMed - as supplied by publisher]Related articles

The use of nilotinib or dasatinib after failure to two prior tyrosine kinase inhibitors (TKI): long-term follow-up.

Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z, Cortes J.

Blood. 2009 Sep 3. [Epub ahead of print]PMID: 19729517 [PubMed - as supplied by publisher]Related articles

Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.

Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S.

Cancer. 2009 Aug 25;115(23):5490-5498. [Epub ahead of print]PMID: 19708032 [PubMed - as supplied by publisher]Related articles

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?

Kantarjian H, O'Brien S, Ravandi F, Borthakur G, Faderl S, Bueso-Ramos C, Abruzzo L, Pierce S, Shan J, Issa JP, Garcia-Manero G.

Cancer. 2009 Nov 15;115(22):5202-9.PMID: 19691096 [PubMed - in process]Related articles

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.

Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ.

Leuk Res. 2009 Jul 29. [Epub ahead of print]PMID: 19646755 [PubMed - as supplied by publisher]Related articles

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure.

Quintás-Cardama A, De Souza Santos FP, Kantarjian H, O'Brien S, Faderl S, Awais A, Borthakur G, Cortes J.

Cancer. 2009 Sep 1;115(17):3935-43.PMID: 19517473 [PubMed - indexed for MEDLINE]Related articles

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.

Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J.

Cancer. 2009 Aug 15;115(16):3709-18.PMID: 19517462 [PubMed - indexed for MEDLINE]Related articles

Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.

Borthakur G, Lin E, Jain N, Estey EE, Cortes JE, O'Brien S, Faderl S, Ravandi F, Pierce S, Kantarjian H.

Cancer. 2009 Jul 15;115(14):3217-21.PMID: 19441109 [PubMed - indexed for MEDLINE]Related articles

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.

Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, Williams S, Burris H 3rd, Faderl S, Estrov Z, Curtin P, Larson RA, Keck JG, Jones M, Meng L, Brown GL.

J Hematol Oncol. 2009 May 13;2:20.PMID: 19439093 [PubMed - in process]Related articlesFree article

Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.

Faderl S, Pal A, Bornmann W, Albitar M, Maxwell D, Van Q, Peng Z, Harris D, Liu Z, Hazan-Halevy I, Kantarjian HM, Estrov Z.

Cancer Res. 2009 May 1;69(9):3910-7. Epub 2009 Apr 21.PMID: 19383925 [PubMed - indexed for MEDLINE]Related articles

Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.

Vega-Ruiz A, Faderl S, Estrov Z, Pierce S, Cortes J, Kantarjian H, Ravandi F.

Int J Hematol. 2009 May;89(4):489-96. Epub 2009 Apr 2.PMID: 19340529 [PubMed - indexed for MEDLINE]Related articles

Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.

Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D, Pierce S, O'Brien S.

Cancer. 2009 May 15;115(10):2147-54.PMID: 19298009 [PubMed - indexed for MEDLINE]Related articles

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome.

Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F.

Leukemia. 2009 Jul;23(7):1297-302. Epub 2009 Feb 26.PMID: 19242494 [PubMed - indexed for MEDLINE]Related articles

Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.

Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M.

J Clin Oncol. 2009 Apr 1;27(10):1637-43. Epub 2009 Feb 17.PMID: 19224852 [PubMed - indexed for MEDLINE]Related articles

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.

De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F.

Bone Marrow Transplant. 2009 Jun;43(11):839-43. Epub 2009 Jan 19.PMID: 19151791 [PubMed - indexed for MEDLINE]Related articles

Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.

Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F.

Cancer. 2009 Jan 1;115(1):101-6.PMID: 19090005 [PubMed - indexed for MEDLINE]Related articles

Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H.

J Clin Oncol. 2009 Feb 1;27(4):504-10. Epub 2008 Dec 15.PMID: 19075265 [PubMed - indexed for MEDLINE]Related articles

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.

Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J.

Blood. 2009 Mar 5;113(10):2154-60. Epub 2008 Dec 5.PMID: 19060245 [PubMed - indexed for MEDLINE]Related articles

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV.

Blood. 2009 Apr 2;113(14):3168-71. Epub 2008 Dec 2.PMID: 19050308 [PubMed - indexed for MEDLINE]Related articles

Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.

Faderl S, Ferrajoli A, Frankfurt O, Pettitt A.

Leukemia. 2009 Mar;23(3):457-66. Epub 2008 Nov 6. Review.PMID: 18987653 [PubMed - indexed for MEDLINE]Related articles

Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.

Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, Brandt M, Estey E.

J Clin Oncol. 2008 Dec 10;26(35):5684-8. Epub 2008 Oct 27.PMID: 18955453 [PubMed - indexed for MEDLINE]Related articles

Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.

Borthakur G, Kantarjian H, Wang X, Plunkett WK Jr, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH.

Cancer. 2008 Dec 1;113(11):3181-5.PMID: 18932257 [PubMed - indexed for MEDLINE]Related articles

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD.

Blood. 2009 Jan 8;113(2):299-305. Epub 2008 Oct 17.PMID: 18931344 [PubMed - indexed for MEDLINE]Related articles

Outcome of adults with acute lymphocytic leukemia after second salvage therapy.

O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM.

Cancer. 2008 Dec 1;113(11):3186-91.PMID: 18846563 [PubMed - indexed for MEDLINE]Related articles

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.

Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey E.

Blood. 2009 Jan 1;113(1):28-36. Epub 2008 Sep 30.PMID: 18827183 [PubMed - indexed for MEDLINE]Related articles

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.

Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ.

Cancer. 2008 Oct 1;113(7 Suppl):1933-52. Review.PMID: 18798533 [PubMed - indexed for MEDLINE]Related articlesFree article

Clofarabine combinations as acute myeloid leukemia salvage therapy.

Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM.

Cancer. 2008 Oct 15;113(8):2090-6.PMID: 18756533 [PubMed - indexed for MEDLINE]Related articlesFree article

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.

O'Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H.

Cancer. 2008 Oct 15;113(8):2097-101.PMID: 18720356 [PubMed - indexed for MEDLINE]Related articlesFree article

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM.

Blood. 2009 Jun 18;113(25):6330-7. Epub 2008 Aug 14.PMID: 18703706 [PubMed - indexed for MEDLINE]Related articles

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Cancer. 2008 Sep 15;113(6):1338-43.PMID: 18629842 [PubMed - indexed for MEDLINE]Related articlesFree article

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.

Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM.

Blood. 2008 Sep 1;112(5):1638-45. Epub 2008 Jun 18.PMID: 18565853 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.

Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H.

Clin Cancer Res. 2008 Jun 15;14(12):3906-15.PMID: 18559612 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.

Borthakur G, Alvarado Y, Ravandi-Kashani F, Cortes J, Estrov Z, Faderl S, Ivy P, Bueso-Ramos C, Nebiyou Bekele B, Giles F.

Cancer. 2008 Jul 15;113(2):360-6.PMID: 18473351 [PubMed - indexed for MEDLINE]Related articlesFree article

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.

Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ.

Invest New Drugs. 2008 Aug;26(4):331-8. Epub 2008 Apr 19.PMID: 18425419 [PubMed - indexed for MEDLINE]Related articles

Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.

Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E.

Leuk Res. 2008 Oct;32(10):1505-9. Epub 2008 Apr 10.PMID: 18405972 [PubMed - indexed for MEDLINE]Related articles

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.

Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H.

Leuk Lymphoma. 2008 Apr;49(4):690-5.PMID: 18398735 [PubMed - indexed for MEDLINE]Related articles

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ.

Blood. 2008 Jun 1;111(11):5291-7. Epub 2008 Mar 11.PMID: 18334676 [PubMed - indexed for MEDLINE]Related articlesFree article

Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia.

Faderl S, Gandhi V, Kantarjian HM.

Curr Opin Hematol. 2008 Mar;15(2):101-7. Review.PMID: 18300755 [PubMed - indexed for MEDLINE]Related articles

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ.

Eur J Haematol. 2008 Apr;80(4):296-8. Epub 2007 Dec 21.PMID: 18182081 [PubMed - indexed for MEDLINE]Related articles

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J.

Cancer. 2008 Feb 15;112(4):837-45.PMID: 18085610 [PubMed - indexed for MEDLINE]Related articlesFree article

A prognostic score for patients with lower risk myelodysplastic syndrome.

Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H.

Leukemia. 2008 Mar;22(3):538-43. Epub 2007 Dec 13.PMID: 18079733 [PubMed - indexed for MEDLINE]Related articles

WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.

Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z.

Cancer Res. 2007 Dec 1;67(23):11291-9.PMID: 18056455 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM.

Blood. 2008 Feb 1;111(3):1060-6. Epub 2007 Oct 25.PMID: 17962510 [PubMed - indexed for MEDLINE]Related articlesFree article

Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.

Borthakur G, Lin E, Faderl S, Ferrajoli A, Wierda W, Giles F, Browning ML, Kantarjian H, Keating M, O'Brien S.

Cancer. 2007 Dec 1;110(11):2478-83.PMID: 17960607 [PubMed - indexed for MEDLINE]Related articlesFree article

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.

Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ.

J Clin Oncol. 2007 Oct 10;25(29):4648-56.PMID: 17925562 [PubMed - indexed for MEDLINE]Related articles

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.

Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG.

Leuk Lymphoma. 2007 Oct;48(10):1931-9.PMID: 17917961 [PubMed - indexed for MEDLINE]Related articles